|View printer-friendly version|
|April 18, 2016 8:00 a.m.|
|Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.|
First-HD Study shows improvements in Total Motor Score and Swallowing Function in Huntington disease patients treated with SD-809
“With limited options for patients living with Huntington disease, there
is a great need for therapies,” said
A total of 90 patients were enrolled in the First-HD study for evaluation over 13 weeks. Patients underwent dose titration over the initial 8 weeks of treatment followed by 4 weeks of maintenance therapy. The overall treatment period was 12 weeks, followed by a 1-week washout period. The Phase III First-HD study data showed that deutetrabenazine improved chorea. The most common adverse reactions reported (≥5% and greater than placebo) were: somnolence, dry mouth, diarrhea, insomnia, and fatigue.
Platform Session details follow:
Presentation: Rating Swallowing Function in Patients with Huntington
Disease Enrolled in the First-HD Study
In the Phase III First-HD study, data showed deutetrabenazine significantly improved swallowing as measured by the Swallowing Disturbance Questionnaire (SDQ).
Presentation: Deutetrabenazine Effect on Total Motor Score in
Patients with Huntington Disease (First-HD)
This additional data set shows significant improvement in total motor score (TMS) with contributions from improved dystonia.
About Huntington Disease
Huntington disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Onset of HD symptoms typically occurs in middle age, but the disease also manifests in children and the elderly. HD is the most common genetic cause of abnormal involuntary writhing movements called chorea.
SD-809 (deutetrabenazine) is an investigational, oral, small-molecule
inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being
developed for the treatment of chorea associated with Huntington disease
(HD). Deutetrabenazine has been granted Orphan Drug Designation for the
treatment of HD by the
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to consummate the acquisition of